This company might be worth far more than many realize.If I had to buy one share of any biotech with no price restriction, I'd naturally gravitate toward the most successful companies in the industry. However, the exercise becomes more complicated if you stipulate a limit of $50 per share; most of the prominent biotech stocks are trading well above that amount.Those around that level are, disproportionately, relatively small and risky companies whose prospects don't look all that strong. Still, at least one ...

Company Performance - CRISPR Therapeutics AG closed at $48.51, reflecting a -0.84% change from the previous day, which is worse than the S&P 500's daily loss of 0.18% [1] - The stock has increased by 1.54% over the past month, while the Medical sector has declined by 3.03% and the S&P 500 has gained 4.46% [1] - The upcoming earnings disclosure is anticipated, with expected EPS of -$1.33, representing a 5.67% increase from the prior-year quarter [1] - For the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$5.55 per share and revenue of $64.2 million, indicating changes of -186.08% and -82.7% from the previous year [1] Analyst Estimates - Recent changes to analyst estimates for CRISPR Therapeutics AG reflect evolving short-term business trends, with upward revisions indicating analysts' positivity towards the company's operations [2] - The Zacks Rank system, which includes estimate changes, has shown that 1 ranked stocks yield an average annual return of +25% since 1988 [2] - Over the past month, there has been a 0.52% rise in the Zacks Consensus EPS estimate, and CRISPR Therapeutics AG currently holds a Zacks Rank of 2 (Buy) [2] Industry Overview - The Medical - Biomedical and Genetics industry is part of the Medical sector and currently holds a Zacks Industry Rank of 87, placing it in the top 35% of over 250 industries [3] - The Zacks Industry Rank measures the strength of industry groups by the average Zacks Rank of individual stocks, with top-rated industries outperforming the bottom half by a factor of 2 to 1 [3]

Core Viewpoint - CRISPR Therapeutics AG (CRSP) shows potential for significant upside based on analysts' price targets and positive earnings estimate revisions, despite skepticism around the reliability of price targets as investment indicators [1][2][5]. Price Targets - The mean price target for CRSP is $81.96, indicating a 67.5% upside potential from the current price of $48.92 [1]. - Price targets range from a low of $30 to a high of $199, with a standard deviation of $34.57, suggesting variability in analysts' estimates [1]. - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement direction [4]. Earnings Estimates - Analysts have shown increasing optimism about CRSP's earnings prospects, with a 0.5% increase in the Zacks Consensus Estimate for the current year [5]. - There has been strong agreement among analysts in revising EPS estimates higher, which correlates with potential near-term stock price movements [5]. - CRSP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [5]. Analyst Behavior - Analysts' price targets may often be overly optimistic due to business incentives, which can lead to inflated estimates [3]. - Despite the skepticism surrounding price targets, the direction implied by these targets can still serve as a useful guide for investors [6].

CRISPR Therapeutics AG (CRSP) closed at $48.05 in the latest trading session, marking a +0.47% move from the prior day. The stock's performance was ahead of the S&P 500's daily loss of 0.76%. On the other hand, the Dow registered a loss of 0.75%, and the technology-centric Nasdaq decreased by 1.01%. The the stock of company has risen by 0.18% in the past month, leading the Medical sector's loss of 3.35% and undershooting the S&P 500's gain of 4.31%. The investment community will be closely monitoring the pe ...

They won't remain southbound forever. CRISPR Therapeutics (CRSP 3.22%) and Moderna (MRNA 2.57%) have much in common. They're both innovative biotechs working in relatively newer niches of this booming industry. However, they've moved in the wrong direction this year. CRISPR's shares are down by 27% year to date, and Moderna's are down by 41%. Regardless of their performances so far in 2024, both stocks are worth investing in this month. Read on to find out why. 1. CRISPR Therapeutics CRISPR Therapeutics rec ...

CRISPR Therapeutics is trading around multiyear lows. Finding an undervalued growth stock can lead to some oversize returns in the long run. In some cases, it can be as simple as focusing on sectors of the market that might not be getting much attention of late, and thus could make for attractive under-the-radar investments right now. One stock that has been struggling and that arguably should be doing a lot better these days is CRISPR Therapeutics (CRSP 1.05%). There was a lot of excitement around the heal ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $45.71, demonstrating a +0.29% swing from the preceding day's closing price. The stock exceeded the S&P 500, which registered a gain of 0.01% for the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Coming into today, shares of the company had gained 0.13% in the past month. In that same time, the Medical sector lost 3.6%, while the S&P 500 gained 1.21%. Analysts and investors alike will be ke ...

Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. It's not fun missing out when a hot stock goes wild. The viral popularity of injectable diabetes and weight loss drugs, called GLP-1s, propelled pharmaceutical stock Novo Nordisk to over 350% in returns over the past five years. That sizeable return beat the broader market by a comfortable margin. But you needn't worry if you feel that you've missed out. The great thing about investing is th ...

Bargain hunters should love these great stocks. By most metrics, the stock market is priced at a premium these days. But that doesn't mean bargains can't still be found. Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (CRSP -2.65%), Gilead Sciences (GILD 0.05%), and Pfizer (PFE -0.81%). You can still get in on the ground floor Prosper Junior Bakiny (CRISPR Therapeutics): Valuing relatively small biotech compani ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%. The the stock of company has fallen by 0.8% in the past month, lagging the Medical sector's gain of 1.53% and the S&P 500's gain of 1.27%. Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming ea ...